
We thank Dr Khan and colleagues, Dr Ansarin and colleagues and Dr Andreica and colleagues for their correspondence in relation to our paper.1–4 The reported experience of Dr Khan and colleagues2 in using anti-interleukin (IL)-6 therapy in the treatment of COVID-19 is interesting, and although there has been much positive observational data reported on the value of anti-IL-6 therapy in COVID-19, including in this journal,5 preliminary reports from two randomised trials have not shown benefit.6,7 When further data are published on anti-IL-6 therapy in treating COVID-19, we can hopefully understand better if this therapy will have a place. Detailed cytokine analysis of 1484 patients with COVID-19 found that IL-6 and tumour necrosis factor (TNF) were independent and significant predictors of poor outcome.2 Therefore, TNF also seems to play an important role in severe COVID-19 and our paper reported a reduced odds of hospitalisation in those taking anti-TNF therapy compared with those not receiving any disease modifying anti-rheumatic drugs (DMARDs).1 Efforts are underway to assess whether anti-TNF treatment is an effective therapy in COVID-19 in the form of the UK-based CATALYST trial (ISRCTN40589030).9

Dr Andreica and colleagues report that 80% of patients underwent a shared decision with their physician about the management of their rheumatic disease during the early part of the pandemic.4 This provides reassurance that patients are choosing to consult their doctor about potential changes to their rheumatic therapy. Changes to therapy may or may not reduce risk of poor outcomes from COVID-19 and may expose the patient to risks of disease flare, new disease complications or Addisonian crisis; therefore, doing this in conjunction with a doctor is the best way to ensure that all the consequences of altering therapy are considered and weighted appropriately.

Dr Ansarin and colleagues report the outcome of 30 patients with autoimmune disease treated with immunomodulatory medications.4 It is reassuring that their outcomes do not differ from the comparison group of 381 patients also detailed in the report. D’Silva and colleagues also recently examined 52 patients with rheumatic disease and 104 comparison patients and found no difference in hospitalisation, length of stay or death. However, they did find an increased rate of intensive care admission/mechanical ventilation in patients with rheumatic disease.10 As further data are published, we can further understand the risk profile of patients with rheumatic disease with COVID-19.

Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson
1Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA
2Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK
3MRC Centre for Neuromuscular Diseases, University College London, London, UK
4Rheumatology, University College London Centre for Rheumatology, London, UK
5Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia
6Metro North Hospital & Health Service, Royal Brisbane and Woman’s Hospital Health Service District, Herston, Queensland, Australia

Correspondence to Dr Philip C Robinson, Faculty of Medicine, The University of Queensland, Herston, QLD 4072, Australia; philip.robinson@uq.edu.au

Handling editor Josef S Smolen
Twitter Pedro M Machado @pedrommcmachado and Philip C Robinson @philiprobinson

Contributors PCR drafted the correspondence. All authors edited and provided approval of the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests MG reports grants from National Institutes of Health, NIAMS, outside the submitted work; KLH reports she has received speaker’s fees from Abbvie and grant income from BMS, UCb and Pfizer, all unrelated to this manuscript. KLH is also supported by the NHIR Manchester Biomedical Research Centre; JY reports personal fees from Astra Zeneca, personal fees from Eli Lilly, grants from Pfizer, outside the submitted work; PMM reports personal fees from Abbvie, personal fees from Eli Lilly, personal fees from Novartis, personal fees from UCB, outside the submitted work. PCR reports personal fees from Abbvie, Eli Lilly, Gilead, Jansen, Novartis, Pfizer, Roche, UCB Pharma and non-financial support from BMS and Roche, outside the submitted work.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.


Received 4 August 2020
Accepted 5 August 2020

http://dx.doi.org/10.1136/annrheumdis-2020-218528
http://dx.doi.org/10.1136/annrheumdis-2020-218609
http://dx.doi.org/10.1136/annrheumdis-2020-218737


ORCID iDs
Pedro M Machado http://orcid.org/0000-0002-8411-7972
Philip C Robinson http://orcid.org/0000-0002-3156-3418
REFERENCES


